Conference abstractPublished 22 Jul 2019
Potentiating new neurological pain drugs from cannabis (CBD/THC)
Medlab Clinical LTD, Australia
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Neurology is a complex area, potentially requiring a combination of surgical and non-surgical intervention. Regardless of the intervention plan, neurology is hindered with a number of co-morbidities that can diminish patient outcomes, one in particular is pain. Pain management requires a number of pharmaceutical agents principally from the opioid class of drugs, potentiating heightened secondary organ toxicity profiles. Further it is accepted that some 33% + of patients undergoing chemotherapy will state that their pain is under-managed. Cannabinoids potentiate new treatments in pain management and posit opioid reduction. Theoretically, the argument appears sound; in real world practice, cannabinoid preparations differ vastly ultimately affecting the efficacy of the final product. This presentation will take a first-hand look at Medlab’s work into developing a standardised and validated “early” drug used in clinical trial and suited for Regulatory (TGA, FDA, EMA) acceptance.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectNeuroscience & Neurology
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Sean Hall”